WinstonWınston
Vetoquinol S.A. logo

Vetoquinol S.A.

VETO.PA
47
Drug Manufacturers - Specialty & Generic · Healthcare
Also trades as: 0O1O.L
Price
€72.10
-0.50 (-0.69%)
Market Cap
€838.1M
Exchange
Euronext Paris
Winston Score
47
Winston is serious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 10, 2026 · filings through Dec 31, 2025

Vetoquinol is a French company that makes medicines and health products for animals. Its main customers are veterinarians, farmers, and pet owners. The company focuses on companion animals like dogs and cats, as well as livestock such as cattle and pigs, and it sells products including antibiotics, anti-inflammatories, and nutritional supplements.

Vetoquinol earns money by selling these veterinary products directly to vets and through distributors. It operates in over 30 countries, with a strong presence in Europe, North America, and emerging markets, and generates roughly €500 million in annual revenue. The founding Frechin family still controls the company, which gives it a stable, long-term ownership structure, but its relatively small size means it competes against much larger players like Zoetis and Boehringer Ingelheim. The key growth driver is the continued rise in pet ownership globally, though pricing pressure from generic competitors and currency fluctuations remain ongoing risks.

Winston Score History

Share count broadly stable

+0.5% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 11.8M (2021) → 11.9M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
7.5%
Thin — 7.5% gross margin
Operating Margin
14.3%
Healthy — 14.3% operating margin
ROCE
6.5%
Weak — 6.5% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-2.5%
Shrinking sales (-2.5% YoY)
EPS YoY
-3.0%
Earnings shrinking (-3.0% YoY)

Slight earnings drop. Typical near a cyclical low.

EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
129%
Turns 129% of profit into real cash
FCF Margin
10.8%
Modest free cash flow (10.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.00
Conservative — low debt load (0.00)
Interest Cover
58.36x
Comfortably covers interest (58.4x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
15.0x
Attractive valuation — P/E 15.0

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
-0.4
SLOWING
Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
1.28%
Small dividend — 1.28% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth
+60.6%
Dividend growing fast (60.6% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial